Navigation Links
A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe
Date:2/17/2009

A Therapy's Effect on Executive Function and Functional Capacity are the Attributes that Most Influence Psychiatrists' Prescribing Habits, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if a drug were to receive formal regulatory approval for the treatment of cognitive impairment associated with schizophrenia (CIAS), such an agent could earn up to 50 percent patient share in the United States and up to 33 percent patient share in Europe, according to surveyed U.S. and European psychiatrists.

The new report entitled Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug finds that a therapy's effect on executive function (reasoning and problem solving) and functional capacity (ability to manage daily tasks) are the attributes that most influences psychiatrists' prescribing decisions in CIAS. To date, no drugs are formally approved for CIAS and off-label treatment is sporadic. However, clinical data and the opinions of interviewed thought leaders indicate that the currently-available therapy, modafinil (Cephalon's Provigil), as well as emerging agents from Roche/Memory Pharmaceuticals, Allon Therapeutics, Cephalon and Merck could demonstrate advantages in treating CIAS when compared with donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in this virtually untapped market.

"In rare cases when psychiatrists elect to prescribe off-label therapy for CIAS, such as donepezil, their choice of treatment is based in large part on a drug's proven benefits in other indications in the hopes that CIAS patients will experience similar benefits," said Decision Resources Analyst Jonathan Searles. "However, thanks to evolving consensus about clinical trial design and the most promising drug targets in CIAS, a growing number of developers are investigating novel compounds for the treatment of this new indication."

About the Report

Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources                   Decision Resources, Inc.
    Christopher Comfort                  Elizabeth Marshall
    781-296-2597                         781-296-2563
    ccomfort@dresources.com              emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. i.HUG Foundation Receives International Grant: Hires a School Nurse to Improve Student Health and Learning
2. Emageon Receives Escrowed Funds and Terminates Merger Agreement
3. Children's National Medical Center Trauma Center Receives Highest Verification from American College of Surgeons
4. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
5. Rising Medical Solutions Receives URAC Workers Compensation Utilization Management Accreditation
6. Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award
7. Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award
8. Boston Medical Center cardiologist receives Drake Award
9. Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
10. Blue Cross Receives Disease Management Awards
11. ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... Recently, patients ... in Southwest Michigan, joined other volunteers and organizations in support of the annual Binder ... children and families dressed up in colorful costumes of all designs coming out to ...
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers of ... EB15•LE® electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 at ... Show is the shooting, hunting and outdoor trade show and conference for the ...
(Date:1/16/2017)... Houston, TX (PRWEB) , ... January 16, 2017 ... ... dental office , Antoine Dental Center, is currently offering complimentary consultations and ... can have their teeth examined for bite irregularities and learn about their orthodontic ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
(Date:1/16/2017)... OR (PRWEB) , ... January 16, 2017 , ... ... author, editor, attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading ... Kent Heckenlively to her nationally syndicated radio program, The Sharon Kleyne Hour Power ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017 Summary ... Outlook to 2022", provides key market data on the ... in millions of US dollars, volume (in units) and ... X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). The ... for each of these market segements, and global corporate-level ...
(Date:1/16/2017)... 2017 Infusion pumps and accessories are ... medications in a controlled, precise and automated manner. ... in critical care, pain management and other applications, ... feel comfortable and pain free. These infusion systems ... to serious life threatening circumstances or even sometimes ...
(Date:1/16/2017)...  Verathon ® Inc., a leading manufacturer and marketer of ... ® Spectrum TM Single-Use video laryngoscopes. The ... Ambient Light Reduction TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) ...
Breaking Medicine Technology: